PHIBRO ANIMAL HEALTH CORP 8-K

What Happened
Phibro Animal Health Corporation announced on April 27, 2026 that Brazil’s Ministry of Agriculture and Livestock (MAPA) published Ordinance No. 1617, which prohibits the importation, manufacture, marketing and use of performance‑enhancing feed additives containing antimicrobials classified as important in human or veterinary medicine. The ordinance names products including Phibro’s virginiamycin and bacitracin; the ban will take effect after a 180‑day transition period. Phibro said it is engaged with MAPA on new registrations for virginiamycin for therapeutic use in cattle and broiler chickens (in final review and expected during the transition), and that its bacitracin product already carries therapeutic claims in Brazil. Based on the 180‑day transition, the company expects the regulatory change to have limited impact on fiscal 2026 results.

Key Details

• Ordinance No. 1617 published by MAPA on April 27, 2026.
• 180‑day transition period from the ordinance date before prohibitions take effect.
• Affected Phibro products specifically cited: virginiamycin and bacitracin.
• Phibro’s virginiamycin therapeutic registrations for cattle and broilers are in final review and expected during the transition; bacitracin already has therapeutic claims in Brazil.

Why It Matters
This is a regulatory change that affects products Phibro sells in Brazil. The 180‑day transition window and the company’s pending therapeutic registrations mean immediate disruption to sales in fiscal 2026 is expected to be limited, per the company’s statement. Investors should note the company’s ongoing regulatory engagement and that longer‑term impacts will depend on MAPA’s final approvals and how customers respond once the transition period ends.